𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine

✍ Scribed by H. Lôo; J. Saiz-Ruiz; J. A. Costa e Silva; M. Ansseau; R. Herrington; A. Vaz-Serra; H. Dilling; S. De Risio

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
137 KB
Volume
16
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Depression is treated by a great variety of antidepressant treatments. SSRIs (such as fluoxetine) are well known: it is, however, sure that further progress is needed and the search for antidepressants with other mechanisms of action (such as tianeptine) or different efficacy is still of interest. A multinational study compared tianeptine with fluoxetine in 387 patients with Depressive Episode, or Recurrent Depressive Disorder, or Bipolar Affective Disorder (ICD-10), in a double-blind parallel group design. They were treated for six weeks. At inclusion, no significant difference between groups was shown. Final MADRS scores were 15.7 and 15.8 with tianeptine and fluoxetine, respectively (ITT population) (p = 0.944). MADRS responders were 58% and 56% with tianeptine and fluoxetine, respectively (p = 0.710). No statistical difference was observed for the other efficacy parameters. Thirty-six withdrawals occurred in each group, without any difference for the reasons of discontinuation. There was no major difference between groups for the other safety parameters. In this study, both tianeptine and fluoxetine exhibited a good efficacy and safety. Copyright 1999 Elsevier Science B. V. All rights reserved.

📜 SIMILAR VOLUMES

Controlled Comparison of Tianeptine, Alp
Controlled Comparison of Tianeptine, Alprazolam and Mianserin in the Treatment of Adjustment Disorders with Anxiety and Depression
✍ MARC ANSSEAU; MICHEL BATAILLE; GUY BRIOLE; ANDRÉ DE NAYER; PIERRE ANDRÉ FAUCHÈRE 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 439 KB 👁 2 views

A multicentre study compared tianeptine (37.5 mg/day), an original psychotropic compound characterized by both antidepressant and anxiolytic potentials, with a reference antidepressant, mianserin (60 mgkday) and a reference anxiolytic, alprazolam (1.5 mglday), in the treatment of 152 patients fulfil

Tianeptine versus fluoxetine in the trea
Tianeptine versus fluoxetine in the treatment of depression complicating Alzheimer's disease
✍ Tomasz M. Sobow; Marcin Maczkiewicz; Iwona Kloszewska 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB

Beeching, 1991) , sometimes transferring their own disquietude at such discussions with relatives on to the reluctance of relatives to talk about DNR issues. Perhaps, in the UK, we need to learn from many of our American colleagues who see it appropriate to formulate an advance directive that comb

A double-blind comparison of the efficac
A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia
✍ Cornelius L. E. Katona; Brian N. Hunter; Julia Bray 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB 👁 2 views

Objectives. To compare the ecacy of paroxetine and imipramine prospectively in patients with coexisting depression and dementia. Methods. An 8-week, double-blind, parallel group trial comparing paroxetine 20±40 mg/day with imipramine 50±100 mg/day in 198 patients aged 60 years or over with a Montgo

Comparison of pramipexole, fluoxetine, a
Comparison of pramipexole, fluoxetine, and placebo in patients with major depression
✍ Mark H. Corrigan; Angelita Q. Denahan; C. Eugene Wright; Rhonda J. Ragual; Dwigh 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB 👁 2 views

Pramipexole, a dopamine D 2 receptor agonist, was tested in 174 patients with major depression, with or without melancholia and without psychotic features. Three daily dose levels (0.375 mg, 1.0 mg, and 5.0 mg) were compared to fluoxetine (Prozac) at 20 mg and placebo in a randomized, double-blind,

Efficacy and safety of quetiapine for de
Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia
✍ Kyoung-Uk Lee; Yang-Whan Jeon; Hae-Kook Lee; Tae-Youn Jun 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB 👁 1 views

## Objective: To investigate the efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia. ## Method: Thirty-nine patients fulfilling dsm-iv-tr diagnostic criteria for schizophrenia and had depressive symptoms were studied in a prospective 6-week open-label design